BUFFALO GROVE, Illinois, November 12, 2013 /PRNewswire/ --
Leica Biosystems announces the launch of the fourth Novocastra™ HD menu, focused on hematopathology. Previously launched were the Novocastra HD menus for breast, head & neck and dermatopathology.
The new Novocastra HD menu for hematopathology is now available for sale in the USA, Canada and the EU. Availability in other regions will follow. The hematopathology menu includes 50 new products. Full details of product availability for the whole Novocastra HD range can be found at http://www.LeicaBiosystems.com/novocastraHD.
In response to customer feedback, Novocastra HD products now feature user-friendly, convenient formats and volumes, ideally suited to laboratory workflow needs. In addition, Leica Biosystems partnered with leading external Quality Assurance (QA) body, NordiQC, to independently* assess each antibody to ensure they perform to the high standards necessary for clinical IHC. This demonstrates Leica Biosystems' commitment to excellence in user convenience and quality.
As a leading provider of reagents and instruments for IHC, Leica Biosystems' goal is to supply superior products that customers can depend on to deliver accurate and reproducible results. When used together with the BOND immunostainer, Novocastra HD offers an advanced staining solution that delivers a new industry standard in staining quality.
Leica Biosystems is a global leader in workflow solutions and automation, striving to advance cancer diagnostics to improve patients' lives. Leica Biosystems provides anatomical pathology laboratories and researchers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting.
The company is represented in over 100 countries. It has manufacturing facilities in 6 countries, sales and service organizations in 19 countries, and an international network of dealers. The company is headquartered in Nussloch, Germany. Further information can be found at http://www.LeicaBiosystems.com
*Independent evaluation by NordiQC according to the manufacturers' instructions for use, commissioned and funded by Leica Biosystems.
SOURCE Leica Biosystems
< Prev | Next > |
---|